Treatment with anti-hypeensive drug spironolactone leads to formation of spironolactone bodies in:
## **Core Concept**
Spironolactone is a potassium-sparing diuretic that acts as an aldosterone antagonist. It is primarily used in the treatment of hypertension and heart failure. The drug works by blocking the effects of aldosterone, leading to the excretion of sodium and water and the retention of potassium.
## **Why the Correct Answer is Right**
Spironolactone bodies, also known as spironolactone-induced crystals or pseudonuclear inclusions, are characteristic histological findings in the kidneys of patients treated with spironolactone. These bodies are formed due to the accumulation of crystals within the lysosomes of renal tubular cells, particularly in the distal convoluted tubules and collecting ducts. The formation of spironolactone bodies is a result of the drug's mechanism of action and its metabolites binding to and accumulating within these cells.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while spironolactone does affect electrolyte balance, the formation of spironolactone bodies is more specifically related to the renal effects of the drug rather than a general effect on electrolyte balance.
- **Option B:** This option is incorrect because, although the liver metabolizes spironolactone, the formation of spironolactone bodies is not primarily associated with liver histology.
- **Option C:** This option is incorrect because the adrenal glands produce aldosterone, which spironolactone antagonizes, but the drug does not cause the formation of spironolactone bodies in the adrenal glands.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that spironolactone bodies are a benign finding and are not indicative of renal damage caused by the drug. They are a consequence of the drug's presence in the body and can be seen in the kidneys of patients on spironolactone therapy.
## **Correct Answer:** .